PBYI Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 115762 min ago

@ $7.35

Wydano: 14 vas. 2024 @ 22:31

Zwrot: -33.88%

Poprzedni sygnał: vas. 13 - 22:35

Poprzedni sygnał: Sprzedaż

Zwrot: 18.17 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally...

Stats
Dzisiejszy wolumen	388 031
Średni wolumen	585 132
Kapitalizacja rynkowa	234.29M
EPS	$0 ( 2024-05-02 )
Następna data zysków	( $-0.220 ) 2024-06-18
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	10.80
ATR14	$0.00900 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Auerbach Alan H	Buy	6 577	Common Stock
2024-03-15	Auerbach Alan H	Buy	9 047	Stock Option (Right to Buy)
2024-02-12	Wong Alvin F	Buy	43 307	Common Stock
2024-02-12	Wong Alvin F	Buy	59 946	Stock Option (Right to Buy)
2024-02-12	Nougues Maximo F	Buy	43 307	Common Stock

INSIDER POWER
69.70
Last 99 transactions
Buy: 2 879 886 \| Sell: 561 464

Wolumen Korelacja

Długi: 0.14 (neutral)

Krótki: -0.68 (moderate negative)

Signal:(32.798) Neutral

Puma Biotechnology Inc Korelacja

10 Najbardziej pozytywne korelacje
FAT	0.831
OHAA	0.828
ISEM	0.815

10 Najbardziej negatywne korelacje
RMRM	-0.839

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Puma Biotechnology Inc Korelacja - Waluta/Towar

0.50
( neutral )

0.48
( neutral )

0.00
( neutral )

0.48
( neutral )

-0.45
( neutral )

Puma Biotechnology Inc Finanse

Annual	2023
Przychody:	$235.64M
Zysk brutto:	$172.96M (73.40 %)
EPS:	$0.460

FY	2023
Przychody:	$235.64M
Zysk brutto:	$172.96M (73.40 %)
EPS:	$0.460

FY	2022
Przychody:	$228.00M
Zysk brutto:	$172.90M (75.83 %)
EPS:	$0.0204

FY	2021
Przychody:	$253.16M
Zysk brutto:	$189.45M (74.84 %)
EPS:	$-0.720

Financial Reports:

No articles found.

Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.